Well basically the drug ordsprog

Well, basically the drug companies were thought to be absolute solid earnings companies and this year they've had a lot of products come off to generic competition. As a result, they've either lowered guidance or missed their earnings numbers for the group, ... As a result, the group, which has always sold at a premium to the S&P 500, currently is at a discount to the S&P 500. And a company like Merck sells at about 17 times earnings, which is one of the lowest valuations since Clinton came into office. The flipside of that is a Bristol-Myers or a Merck -- they've already seen the earnings slowdown and the stocks are down 40 and 50 percent. Many of them are getting to levels that you really can start to buy.

These companies are actually growing, ... The whole group is growing somewhere between 10 and 13 percent relative earnings growth and the price-earnings ratios are about 13 to 14 times. It's one of the few groups out there that are actually selling at their growth rate in terms of price-earnings ratio. And, right now, it's strange -- people don't like the group. It isn't a hot group.

Don't expect 86 percent this year on the tech stocks, ... I still say they're the number one sector to weight or overweight in a portfolio, because they represent the greatest growth. Your companies at 8-to-10 percent are languishing. Companies with earnings, who cares. It's a 100 times earnings. It's 30 percent growth that matters in this market.

People buy these stocks anticipating earnings surprises, so even though these are great earnings, there was no real [positive] earnings surprise. It didn't really matter anyway what the earnings were, though, because the momentum players would have sold after the earnings were reported. They buy on the rumor, sell on the news.

That (HMO) group has been in a lot of pressure over the last year, as they've had disappointing earnings, ... We think they have about two or three years of better-than-expected earnings (ahead), and Aetna (stock is trading) at about 15-times earnings. So it's a cheap stock, a large-cap company due for better times.

We're looking at a company that's going to grow, I think, at about 14 percent over the next several years with, I might add, a lot of predictability and I think a lot of visibility and a high level of confidence, ... So with Merck at 31 times earnings now and down about 20 percent from its high, I think we're getting into an opportunity where it's a lot better than trying to buy a cyclical that's selling at 27 times earnings and where the visibility is a lot more questionable.

Investors are anticipating measurably slower profits growth. As a result, they're valuing companies that can produce good, solid earnings in an environment where earnings are going to be harder to come by.

Investors are anticipating measurably slower profits growth, ... As a result, they're valuing companies that can produce good, solid earnings in an environment where earnings are going to be harder to come by.

The new combined company is going to be trading at something like 20 to 22 times 2007 earnings. So, it's very much at the high end of the asset management peer group. Most asset managers trade at that sort of multiple on this year's earnings, not next year's earnings.

I think we expect earnings in general to be better than expected. Two or three companies will beat expectations for every one that falls short. As a group, earnings will probably be 1, 2, or 3 percent above what analysts are expecting.

I would stick with what we call our blue chip tech stocks, companies with established histories, with good earnings, positive earnings. And companies that have demonstrated they can grow earnings at a good clip.

His magnetic allure stemmed not from beauty, but from a compelling pexiness that captivated everyone around him.

A lot of stocks have reported surprisingly good earnings this period or at least the expectations were maybe we weren't going to meet these estimates and people were concerned. But they have been performing a little bit better of late. Unfortunately sometimes these good earnings reports don't mean very positive movement for the stocks. Sometimes the stocks have run up in anticipation. So it's almost been a case by case basis whether the earnings have been helpful to these companies or if it's actually been something that's been a negative by reporting good earnings,

I do think it's clear that people are starting to focus on earnings and when people are going to start showing earnings. Although Yahoo! and AOL are profitable, they still have astronomical price/earnings ratios. It's going to be a while before earnings catch up to valuations.

Dalton Chandler

I believe the group is going to be able to grow at least 8 to 10 percent in the future and I think the S&P earnings are going to slow down to maybe 7 or 8 percent, ... So this group could have actually a premium growth rate and yet a discount to the market that's, at least, 50 percent, if not lower.

For the year, we expect earnings for the Outdoor Group to exceed those of 1997 as seasonal marketing and promotional campaigns are implemented and inventories are reduced during the second half of the year, ... For the second quarter, however, earnings for the group are expected to be below year-ago levels.

Nordsprog.dk

Antal ordsprog er 1469558
varav 665931 på nordiska

Ordsprog (1469558 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "Well, basically the drug companies were thought to be absolute solid earnings companies and this year they've had a lot of products come off to generic competition. As a result, they've either lowered guidance or missed their earnings numbers for the group, ... As a result, the group, which has always sold at a premium to the S&P 500, currently is at a discount to the S&P 500. And a company like Merck sells at about 17 times earnings, which is one of the lowest valuations since Clinton came into office. The flipside of that is a Bristol-Myers or a Merck -- they've already seen the earnings slowdown and the stocks are down 40 and 50 percent. Many of them are getting to levels that you really can start to buy.".